Kinoxis Therapeutics Pty Revenue
Biotechnology Research • 
Melbourne, Victoria, Australia • 11-20 Employees
Kinoxis Therapeutics Pty revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $63,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,200,000 |
| Total funding | $19,100,000 |
Key Contacts at Kinoxis Therapeutics Pty
Raymond Luong
Associate Director Business Development
Tiina Ahveninen
Director Clinical Operations
Shirley Dong
Associate Director Cmc
Company overview
| Headquarters | Melbourne, Victoria, Australia |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2017 |
| Employees | 11-20 |
| Socials |
Kinoxis Therapeutics Pty Email Formats
Kinoxis Therapeutics Pty uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@kinoxistherapeutics.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@kinoxistherapeutics.com | 100% |
About Kinoxis Therapeutics Pty
Kinoxis Therapeutics Pty Ltd is a private, Australian-based, clinical-stage biotechnology company developing first-in-class therapeutics to address the escalating demand for safe and effective treatments for behavioural and psychological symptoms in neuropsychiatric disorders. Kinoxis’ lead candidate, KNX100, is being developed for the treatment of behavioural and psychological symptoms in neuropsychiatric disorders, including agitation and aggression in dementia, and several substance use disorders. KNX100 has a novel mechanism of action, interacting with disease relevant pharmacological, molecular, and neural targets, to modify the dysregulated brain systems linked with specific behavioural and psychological symptoms in neuropsychiatric disorders. The compound has an extensive pre-clinical data package consisting of multiple cross-species animal efficacy models conducted across several independent research organisations. Kinoxis has completed a Phase 1 study conducted under a US IND and have demonstrated KNX100 to be safe and tolerable in healthy volunteers. Currently, KNX100 is being investigated in the CARES-X Phase 2 clinical trial, a multi-site study in Australia focused exploring its safety, tolerability, and efficacy as a treatment for agitation in dementia. Kinoxis is also advancing clinical programs targeting stimulant, opioid, and alcohol use disorders. Notably, the alcohol use disorder program is being developed in collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), while the opioid use disorder program has received significant funding from the US National Institute of Health/National Institute on Drug Abuse (NIH/NIDA). In addition to the KNX100 program, Kinoxis have a strategic partnership and licensing agreement with Boehringer Ingelheim to develop first-in-class oxytocin receptor targeting precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric disorders.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Kinoxis Therapeutics Pty has 5 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore Kinoxis Therapeutics Pty's funding history, including investment rounds, total capital raised, and key backers.
Kinoxis Therapeutics Pty Tech Stack
Discover the technologies and tools that power Kinoxis Therapeutics Pty's digital infrastructure, from frameworks to analytics platforms.
CDN
Web servers
Miscellaneous
Programming languages
Miscellaneous
Blogs
Analytics
Databases
Page builders
Miscellaneous
Performance
Font scripts
United Kingdom
United States
Finland
Frequently asked questions
4.8
40,000 users
